Celltrion announced the launch of two cancer treatments in Vietnam: Truxima (active ingredient rituximab) for blood cancer and Vegzelma (active ingredient bevacizumab) for metastatic colorectal and breast cancers.
Following the introduction of its autoimmune disease treatment, Remsima (active ingredient infliximab), and the breast and stomach cancer drug Herjuda (active ingredient trastuzumab), the company is expanding its local product portfolio with these two new cancer drugs.
Celltrion plans to leverage its existing distribution network established through Herjuda sales to enhance the supply of Truxima and Vegzelma.
As of 2023, Vietnam's pharmaceutical market is valued at approximately 10 trillion won, having grown at an average annual rate of over 7% over the past decade, emerging as a key market in the region. This robust growth is also seen as an opportunity for regulatory expansion.
Celltrion is broadening its footprint in Southeast Asia, including Vietnam, Thailand, and Malaysia. According to market research firm IQVIA, Remsima holds a 96% market share in Singapore and 77% in Thailand, while Herjuda and Truxima are the top-selling products in Thailand.
The company stated that it has secured market trust by increasing bid success rates and ensuring timely deliveries based on supply stability.
Looking ahead, Celltrion aims to strengthen its presence in emerging markets by expanding its product portfolio and improving bidding outcomes. In Vietnam, it is preparing to launch follow-up products such as Remsima SC and plans to broaden its product range and participate in bids in Indonesia and Latin America.
A Celltrion representative remarked, "The new launch of cancer drugs allows for a more aggressive sales strategy in Vietnam. We will continue to expand the release of high-revenue products, focusing on emerging markets to drive performance growth."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.